TG
Thomas Gad
Chief Business Officer

Thomas Gad insider trades: Y-mAbs Therapeutics (YMAB) stock sales

Chief Business Officer, Y-mAbs Therapeutics Last trade Mar 7, 2025 103 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
96
Open-market trades
since 2019
2
Companies
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Thomas reports to the SEC

Open-market buys and sales

96 trades reported on SEC Form 4, newest first

DateStockTypeValue
Mar 7, 2025YMAB↓ Sell$57K
Sep 16, 2024YMAB↓ Sell$1.3M
Jun 11, 2024YMAB↓ Sell$841K
May 23, 2024YMAB↓ Sell$396K
Mar 5, 2024YMAB↓ Sell$64K
Dec 15, 2023YMAB↓ Sell$1.0M
Nov 21, 2023YMAB↓ Sell$795K
Feb 9, 2022YMAB↓ Sell$2.0M
Feb 4, 2022YMAB↓ Sell$1.1M
Feb 1, 2022YMAB↓ Sell10b5-1$81K
Jan 24, 2022YMAB↓ Sell$936K
Jan 21, 2022YMAB↓ Sell$2.0M
Jan 19, 2022YMAB↓ Sell$761K
Jan 18, 2022YMAB↓ Sell10b5-1$92K
Dec 7, 2021YMAB↓ Sell$901K
Nov 30, 2021YMAB↓ Sell10b5-1$814K
Nov 23, 2021YMAB↓ Sell$853K
Nov 16, 2021YMAB↓ Sell$77K
Oct 29, 2021YMAB↓ Sell$99K
Oct 15, 2021YMAB↓ Sell$109K
Sep 30, 2021YMAB↓ Sell$113K
Sep 15, 2021YMAB↓ Sell$135K
Sep 2, 2021YMAB↓ Sell$1.7M
Aug 17, 2021YMAB↓ Sell$851K
Aug 3, 2021YMAB↓ Sell$135K
Jul 20, 2021YMAB↓ Sell$130K
Jul 7, 2021YMAB↓ Sell$127K
Jun 30, 2021YMAB↓ Sell$135K
Jun 14, 2021YMAB↓ Sell$143K
May 28, 2021YMAB↓ Sell$148K
May 18, 2021YMAB↓ Sell$136K
Apr 26, 2021YMAB↓ Sell10b5-1$196K
Apr 12, 2021YMAB↓ Sell10b5-1$186K
Apr 12, 2021YMAB↓ Sell10b5-1$106K
Apr 1, 2021YMAB↓ Sell10b5-1$272K
Apr 1, 2021YMAB↓ Sell10b5-1$182K
Mar 15, 2021YMAB↓ Sell10b5-1$258K
Mar 15, 2021YMAB↓ Sell10b5-1$147K
Mar 1, 2021YMAB↓ Sell10b5-1$320K
Mar 1, 2021YMAB↓ Sell10b5-1$213K
Feb 16, 2021YMAB↓ Sell10b5-1$330K
Feb 16, 2021YMAB↓ Sell10b5-1$188K
Feb 1, 2021YMAB↓ Sell10b5-1$294K
Feb 1, 2021YMAB↓ Sell10b5-1$168K
Jan 19, 2021YMAB↓ Sell10b5-1$326K
Jan 19, 2021YMAB↓ Sell10b5-1$186K
Jan 5, 2021YMAB↓ Sell10b5-1$346K
Jan 5, 2021YMAB↓ Sell10b5-1$197K
Dec 28, 2020YMAB↓ Sell10b5-1$364K
Dec 16, 2020YMAB↓ Sell10b5-1$371K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Thomas Gad's insider trades

Thomas Gad is Chief Business Officer at Y-mAbs Therapeutics (YMAB). Since Apr 11, 2019, Thomas has reported no open-market purchases and 96 sales worth $47.5M on SEC Form 4. There have been no open-market trades in the last 12 months.

62 sales (23% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.

Their filings also include option exercises (20 filings), grants and awards (9 filings), other transactions (3 filings), gifts (2 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every YMAB insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.